Acute Myeloid Leukemia

Researchers map 'family trees' of acute myeloid leukemia

For the first time, a team of international researchers has mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains ...

Jul 16, 2018
popularity27 comments 0

Professor developing device to administer cancer drug

A new device under development by a nuclear engineering professor will allow doctors to dispense accurate dosages of a drug made with actinium-225, an isotope that has been shown to be effective in treating—and curing—myeloid ...

Jun 27, 2018
popularity1 comments 0

Clinical trials show promise in leukemia

Two drugs that target different mutations showed encouraging results in treating leukemia, according to recent clinical trials published in the New England Journal of Medicine (NEJM) and The Lancet Oncology.

Jul 10, 2018
popularity17 comments 0

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Aggressive immune cells aggravate Parkinson's disease

Parkinson's disease, formerly referred to as "shaking palsy," is one of the most common disorders affecting movement and the nervous system. Medical researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) ...

Understanding the neuroscience of binge drinking

A new study from researchers at Columbia University Irving Medical Center found that binge drinking impairs working memory in the adolescent brain. The study, in mice, explains why teenagers who binge drink are 15 times more ...